Literature DB >> 18692173

Common neural circuitry supporting volitional saccades and its disruption in schizophrenia patients and relatives.

Jazmin Camchong1, Kara A Dyckman, Benjamin P Austin, Brett A Clementz, Jennifer E McDowell.   

Abstract

BACKGROUND: People with schizophrenia and their biological relatives have deficits in executive control processes such as inhibition and working memory as evidenced by performance abnormalities on antisaccade (AS) and ocular motor delayed response (ODR) tasks.
METHODS: The present functional magnetic resonance imaging (fMRI) study was conducted to investigate brain activity associated with these putative indices of schizophrenia risk by: 1) directly comparing neural functioning in 15 schizophrenia patients, 13 of their first-degree biological relatives (primarily siblings), and 14 healthy participants; and 2) assessing executive function associated with volitional saccades by using a combination of AS and ODR tasks.
RESULTS: Behavioral data showed that patients and relatives both made more volitional saccade errors. Imaging data demonstrated that within the context of preserved activity in some neural regions in patients and relatives, there were two distinct patterns of disruptions in other regions. First, there were deficits observed only in the schizophrenia group (decreased activity in lateral frontal eye field and supplementary eye field), suggesting a change associated with disease manifestation. Second, there were deficits observed in both patients and relatives (decreased activity in middle occipital gyrus, insula, cuneus, anterior cingulate, and Brodmann area 10 in prefrontal cortex), indicating a potential association with disease risk.
CONCLUSIONS: Results indicate that decreased brain activation in regions involved in managing and evaluating early sensory and attention processing might be associated with poor volitional saccade control and risk for developing schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692173      PMCID: PMC3339629          DOI: 10.1016/j.biopsych.2008.06.015

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  89 in total

Review 1.  The antisaccade task as a research tool in psychopathology: a critical review.

Authors:  Samuel B Hutton; Ulrich Ettinger
Journal:  Psychophysiology       Date:  2006-05       Impact factor: 4.016

2.  Neural activity in monkey prefrontal cortex is modulated by task context and behavioral instruction during delayed-match-to-sample and conditional prosaccade-antisaccade tasks.

Authors:  Kevin Johnston; Stefan Everling
Journal:  J Cogn Neurosci       Date:  2006-05       Impact factor: 3.225

3.  Specific executive dysfunction in patients with first-episode medication-naïve schizophrenia.

Authors:  Raymond C K Chan; Eric Y H Chen; C W Law
Journal:  Schizophr Res       Date:  2005-12-02       Impact factor: 4.939

4.  Selection and maintenance of saccade goals in the human frontal eye fields.

Authors:  Clayton E Curtis; Mark D'Esposito
Journal:  J Neurophysiol       Date:  2006-02-08       Impact factor: 2.714

5.  Functional magnetic resonance imaging studies of eye movements in first episode schizophrenia: smooth pursuit, visually guided saccades and the oculomotor delayed response task.

Authors:  Sarah K Keedy; Christen L Ebens; Martcheri S Keshavan; John A Sweeney
Journal:  Psychiatry Res       Date:  2006-03-29       Impact factor: 3.222

6.  Brain activation during antisaccades in unaffected relatives of schizophrenic patients.

Authors:  Mathijs Raemaekers; Nick F Ramsey; Matthijs Vink; Martin P van den Heuvel; Rene S Kahn
Journal:  Biol Psychiatry       Date:  2005-09-13       Impact factor: 13.382

7.  Basal ganglia-thalamocortical circuitry disruptions in schizophrenia during delayed response tasks.

Authors:  Jazmin Camchong; Kara A Dyckman; Caroline E Chapman; Nathan E Yanasak; Jennifer E McDowell
Journal:  Biol Psychiatry       Date:  2006-02-03       Impact factor: 13.382

8.  Antisaccade performance in monozygotic twins discordant for schizophrenia: the Maudsley twin study.

Authors:  Ulrich Ettinger; Marco Picchioni; Mei-Hua Hall; Katja Schulze; Timothea Toulopoulou; Sabine Landau; Trevor J Crawford; Robin M Murray
Journal:  Am J Psychiatry       Date:  2006-03       Impact factor: 18.112

9.  Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration.

Authors:  Adam L Boxer; Siobhan Garbutt; Katherine P Rankin; Joanna Hellmuth; John Neuhaus; Bruce L Miller; Stephen G Lisberger
Journal:  J Neurosci       Date:  2006-06-07       Impact factor: 6.167

Review 10.  Genetic bases for endophenotypes in psychiatric disorders.

Authors:  Wade H Berrettini
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

View more
  30 in total

1.  Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia.

Authors:  Ulrich Ettinger; Anne Schmechtig; Timothea Toulopoulou; Charmaine Borg; Claire Orrells; Sheena Owens; Kazunori Matsumoto; Neeltje E van Haren; Mei-Hua Hall; Veena Kumari; Philip K McGuire; Robin M Murray; Marco Picchioni
Journal:  Schizophr Bull       Date:  2010-06-10       Impact factor: 9.306

2.  Abnormally persistent fMRI activation during antisaccades in schizophrenia: a neural correlate of perseveration?

Authors:  Kara A Dyckman; Adrian K C Lee; Yigal Agam; Mark Vangel; Donald C Goff; Jason J S Barton; Dara S Manoach
Journal:  Schizophr Res       Date:  2011-08-09       Impact factor: 4.939

3.  Impaired volitional saccade control: first evidence for a new candidate endophenotype in obsessive-compulsive disorder.

Authors:  Lisa Kloft; Benedikt Reuter; Anja Riesel; Norbert Kathmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-29       Impact factor: 5.270

4.  Increased SNARE Protein-Protein Interactions in Orbitofrontal and Anterior Cingulate Cortices in Schizophrenia.

Authors:  Alfredo Ramos-Miguel; Clare L Beasley; Andrew J Dwork; J John Mann; Gorazd Rosoklija; Alasdair M Barr; William G Honer
Journal:  Biol Psychiatry       Date:  2014-12-19       Impact factor: 13.382

5.  Response inhibition and response monitoring in a saccadic countermanding task in schizophrenia.

Authors:  Katharine N Thakkar; Jeffrey D Schall; Leanne Boucher; Gordon D Logan; Sohee Park
Journal:  Biol Psychiatry       Date:  2010-10-23       Impact factor: 13.382

6.  Reduced SNAP25 Protein Fragmentation Contributes to SNARE Complex Dysregulation in Schizophrenia Postmortem Brain.

Authors:  Alfredo Ramos-Miguel; Kristina Gicas; Jehan Alamri; Clare L Beasley; Andrew J Dwork; J John Mann; Gorazd Rosoklija; Fang Cai; Weihong Song; Alasdair M Barr; William G Honer
Journal:  Neuroscience       Date:  2018-12-21       Impact factor: 3.590

7.  Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT.

Authors:  Stefano Marenco; Antonina A Savostyanova; Jan Willem van der Veen; Matthew Geramita; Alexa Stern; Alan S Barnett; Bhaskar Kolachana; Eugenia Radulescu; Fengyu Zhang; Joseph H Callicott; Richard E Straub; Jun Shen; Daniel R Weinberger
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

Review 8.  Cognition and brain function in schizotypy: a selective review.

Authors:  Ulrich Ettinger; Christine Mohr; Diane C Gooding; Alex S Cohen; Alexander Rapp; Corinna Haenschel; Sohee Park
Journal:  Schizophr Bull       Date:  2015-03       Impact factor: 9.306

9.  Anomalous use of context during task preparation in schizophrenia: a magnetoencephalography study.

Authors:  Dara S Manoach; Adrian K C Lee; Matti S Hämäläinen; Kara A Dyckman; Jesse S Friedman; Mark Vangel; Donald C Goff; Jason J S Barton
Journal:  Biol Psychiatry       Date:  2013-02-04       Impact factor: 13.382

10.  Effects of ketamine on brain function during response inhibition.

Authors:  M Steffens; C Neumann; A-M Kasparbauer; B Becker; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2018-10-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.